title: Newborn screening programmes including genetic analyses: limits and risks of negative consequences?
authors.forename: Christel
authors.initials: C
authors.lastname: Thauvin-Robinet
authors.forename: Anne
authors.initials: A
authors.lastname: Munck
authors.forename: Michel
authors.initials: M
authors.lastname: Roussey
authors.forename: Frédéric
authors.initials: F
authors.lastname: Huet
authors.forename: Christine
authors.initials: C
authors.lastname: Binquet
authors.forename: Emmanuelle
authors.initials: E
authors.lastname: Girodon
mesh_terms: D003550:Cystic Fibrosis / Q000175:diagnosis / Q000235:genetics*; D019005:Cystic Fibrosis Transmembrane Conductance Regulator / Q000235:genetics; D005060:Europe; D005260:Female; D030342:Genetic Diseases, Inborn / Q000175:diagnosis*; D005820:Genetic Testing; D014943:Global Health; D006801:Humans; D007231:Infant, Newborn; D008297:Male; D015997:Neonatal Screening / Q000379:methods*; D015397:Program Evaluation; D012307:Risk Factors
chemical_list: D019005:Cystic Fibrosis Transmembrane Conductance Regulator